440 related articles for article (PubMed ID: 25724523)
81. Inhibition of DNA-dependent protein kinase induces accelerated senescence in irradiated human cancer cells.
Azad A; Jackson S; Cullinane C; Natoli A; Neilsen PM; Callen DF; Maira SM; Hackl W; McArthur GA; Solomon B
Mol Cancer Res; 2011 Dec; 9(12):1696-707. PubMed ID: 22009179
[TBL] [Abstract][Full Text] [Related]
82. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
83. Targeting epidermal growth factor receptor-associated signaling pathways in non-small cell lung cancer cells: implication in radiation response.
Choi EJ; Ryu YK; Kim SY; Wu HG; Kim JS; Kim IH; Kim IA
Mol Cancer Res; 2010 Jul; 8(7):1027-36. PubMed ID: 20587532
[TBL] [Abstract][Full Text] [Related]
84. AZD2014 Radiosensitizes Oral Squamous Cell Carcinoma by Inhibiting AKT/mTOR Axis and Inducing G1/G2/M Cell Cycle Arrest.
Yu CC; Huang HB; Hung SK; Liao HF; Lee CC; Lin HY; Li SC; Ho HC; Hung CL; Su YC
PLoS One; 2016; 11(3):e0151942. PubMed ID: 27031247
[TBL] [Abstract][Full Text] [Related]
85. Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer.
Ning C; Liang M; Liu S; Wang G; Edwards H; Xia Y; Polin L; Dyson G; Taub JW; Mohammad RM; Azmi AS; Zhao L; Ge Y
Oncotarget; 2017 Jul; 8(27):44295-44311. PubMed ID: 28574828
[TBL] [Abstract][Full Text] [Related]
86. Antitumor activity of enzastaurin as radiation sensitizer in head and neck squamous cell carcinoma.
Yin X; Hayes DN; Shores CG
Head Neck; 2011 Aug; 33(8):1106-14. PubMed ID: 20967867
[TBL] [Abstract][Full Text] [Related]
87. Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways.
Raju U; Riesterer O; Wang ZQ; Molkentine DP; Molkentine JM; Johnson FM; Glisson B; Milas L; Ang KK
Radiother Oncol; 2012 Nov; 105(2):241-9. PubMed ID: 23010482
[TBL] [Abstract][Full Text] [Related]
88. Comprehensive Mutational and Phenotypic Characterization of New Metastatic Cutaneous Squamous Cell Carcinoma Cell Lines Reveal Novel Drug Susceptibilities.
Perry J; Ashford B; Thind AS; Gauthier ME; Minaei E; Major G; Iyer NG; Gupta R; Clark J; Ranson M
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333825
[TBL] [Abstract][Full Text] [Related]
89. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
90. Disrupting the mTOR signaling network as a potential strategy for the enhancement of cancer radiotherapy.
Dumont FJ; Bischoff P
Curr Cancer Drug Targets; 2012 Oct; 12(8):899-924. PubMed ID: 22831276
[TBL] [Abstract][Full Text] [Related]
91. HIV Protease Inhibitors Sensitize Human Head and Neck Squamous Carcinoma Cells to Radiation by Activating Endoplasmic Reticulum Stress.
Liu R; Zhang L; Yang J; Zhang X; Mikkelsen R; Song S; Zhou H
PLoS One; 2015; 10(5):e0125928. PubMed ID: 25933118
[TBL] [Abstract][Full Text] [Related]
92. Targeted radiosensitization by the Chk1 inhibitor SAR-020106.
Borst GR; McLaughlin M; Kyula JN; Neijenhuis S; Khan A; Good J; Zaidi S; Powell NG; Meier P; Collins I; Garrett MD; Verheij M; Harrington KJ
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1110-8. PubMed ID: 22981708
[TBL] [Abstract][Full Text] [Related]
93. Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.
Cassell A; Freilino ML; Lee J; Barr S; Wang L; Panahandeh MC; Thomas SM; Grandis JR
Neoplasia; 2012 Nov; 14(11):1005-14. PubMed ID: 23226094
[TBL] [Abstract][Full Text] [Related]
94. CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy.
Barker HE; Patel R; McLaughlin M; Schick U; Zaidi S; Nutting CM; Newbold KL; Bhide S; Harrington KJ
Mol Cancer Ther; 2016 Sep; 15(9):2042-54. PubMed ID: 27422809
[TBL] [Abstract][Full Text] [Related]
95. AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells.
Raghavan P; Tumati V; Yu L; Chan N; Tomimatsu N; Burma S; Bristow RG; Saha D
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e507-14. PubMed ID: 22795803
[TBL] [Abstract][Full Text] [Related]
96. HPV-positive HNSCC cell lines but not primary human fibroblasts are radiosensitized by the inhibition of Chk1.
Busch CJ; Kriegs M; Laban S; Tribius S; Knecht R; Petersen C; Dikomey E; Rieckmann T
Radiother Oncol; 2013 Sep; 108(3):495-9. PubMed ID: 23932155
[TBL] [Abstract][Full Text] [Related]
97. Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma.
Okui T; Shimo T; Fukazawa T; Mohammad Monsur Hassan N; Honami T; Ibaragi S; Takaoka M; Naomoto Y; Sasaki A
Curr Cancer Drug Targets; 2013 Mar; 13(3):289-99. PubMed ID: 23016912
[TBL] [Abstract][Full Text] [Related]
98. Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress.
Lindemann A; Patel AA; Tang L; Tanaka N; Gleber-Netto FO; Bartels MD; Wang L; McGrail DJ; Lin SY; Frank SJ; Frederick MJ; Myers JN; Osman AA
Mol Cancer Ther; 2021 Jul; 20(7):1257-1269. PubMed ID: 33947685
[TBL] [Abstract][Full Text] [Related]
99. The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.
Anderson RT; Keysar SB; Bowles DW; Glogowska MJ; Astling DP; Morton JJ; Le P; Umpierrez A; Eagles-Soukup J; Gan GN; Vogler BW; Sehrt D; Takimoto SM; Aisner DL; Wilhelm F; Frederick BA; Varella-Garcia M; Tan AC; Jimeno A
Mol Cancer Ther; 2013 Oct; 12(10):1994-2005. PubMed ID: 23873848
[TBL] [Abstract][Full Text] [Related]
100. Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma.
Wong CH; Loong HH; Hui CW; Lau CP; Hui EP; Ma BB; Chan AT
Invest New Drugs; 2013 Dec; 31(6):1399-408. PubMed ID: 23975511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
